In advanced nonsmall cell lung cancer (NSCLC) patients, platinum-based combination
chemotherapy is standard treatment in the first-line setting; however, the large majority of …

Platinum-based doublet chemotherapy with or without bevacizumab is the standard of care
for the initial management of advanced and metastatic non-small cell lung cancer (NSCLC) …

With the improved understanding of driver mutations in non-small cell lung cancer (NSCLC),
expanding the targeted therapeutic options improved the survival and safety. However …

There have been remarkable advances in the targeted treatment of advanced non-small cell
lung cancer (NSCLC) over the past several years. Survival outcomes are steadily improving …

Background: Platinum-based combination chemotherapy is recommended as the standard
treatment for patients with advanced non–small-cell lung cancer (NSCLC), but its benefit is …

Use of platinum-based chemotherapy doublets is the standard of care for patients with
advanced-stage non–small cell lung cancer, being associated with improved survival …

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in the
world. The majority of NSCLC patients are diagnosed with advanced-stage disease and …

Patients with advanced NSCLC receive palliative chemotherapy with platinum-based
doublets. Cisplatin-based doublets are preferred in patients with good performance status …

The therapeutic approach to patients affected by advanced non-small-cell lung cancer
(NSCLC) is facing rapid and continuous evolution. In recent years, the emergence of new …

Platinum-based doublets are the standard first-line therapy for patients with advanced non-
small-cell lung cancer, with approximately a third of patients obtaining an objective response …